Characterization of IDO1 and TDO2 in pediatric central nervous system tumors

被引：0
|
作者：
Lauing, Kristen
Lulla, Rishi
Zhai, Lijie
Hashizume, Rintaro
Fangusaro, Jason
Wainwright, Derek A.
机构：
来源：
CANCER IMMUNOLOGY RESEARCH | 2016年 / 4卷 / 11期
关键词：
D O I：
10.1158/2326-6066.IMM2016-A051
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A051
引用
收藏
页数：2
相关论文
共 50 条
  • [21] AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastoma
    Bickerdike, Michael J.
    Nafia, Imane
    Bessede, Alban
    Chen, Cheng-Bang
    Wangpaichitr, Medhi
    BMC CANCER, 2024, 24 (01)
  • [22] Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive function
    Too, Lay Khoon
    Li, Kong M.
    Suarna, Cacang
    Maghzal, Ghassan J.
    Stocker, Roland
    McGregor, Iain S.
    Hunt, Nicholas H.
    BEHAVIOURAL BRAIN RESEARCH, 2016, 312 : 102 - 117
  • [23] Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors
    Platten, Michael
    Doeberitz, Nikolaus von Knebel
    Oezen, Iris
    Wick, Wolfgang
    Ochs, Katharina
    FRONTIERS IN IMMUNOLOGY, 2015, 5
  • [24] Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice
    Zhang, Rongjie
    Wang, Yuanfeiyi
    Liu, Dan
    Luo, Qing
    Du, Peixin
    Zhang, Haiyan
    Wu, Wenshuang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [25] Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening
    Sari, Suat
    Tomek, Petr
    Leung, Euphemia
    Reynisson, Johannes
    MOLECULES, 2019, 24 (23):
  • [26] Gene Variant Frequencies of IDO1, IDO2, TDO, and KMO in Substance Use Disorder Cohorts
    Contella, Lindsey
    Farrell, Christopher L.
    Boccuto, Luigi
    Litwin, Alain
    Snyder, Marion L.
    GENES, 2024, 15 (11)
  • [27] A comprehensive analysis of TDO2 expression in immune cells and characterization of immune cell phenotype in TDO2 knockout mice
    Li, Susu
    Li, Siyu
    Zhao, Yingjie
    Zhang, Bingjie
    Wang, Xinwei
    Yang, Xuezhi
    Wang, Yueye
    Jia, Chengyan
    Chang, Yan
    Wei, Wei
    TRANSGENIC RESEARCH, 2021, 30 (06) : 781 - 797
  • [28] Discovery of novel IDO1/TDO2 dual inhibitors: a consensus Virtual screening approach with molecular dynamics simulations, and binding free energy analysis
    Hanif, Naufa
    Sari, Suat
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024,
  • [29] Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer
    Wu, Chunjing
    Spector, Sydney A.
    Theodoropoulos, George
    Nguyen, Dan J. M.
    Kim, Emily Y.
    Garcia, Ashley
    Savaraj, Niramol
    Lim, Diane C.
    Paul, Ankita
    Feun, Lynn G.
    Bickerdike, Michael
    Wangpaichitr, Medhi
    CANCER & METABOLISM, 2023, 11 (01)
  • [30] EPL-1410, a novel fused heterocycle based orally active dual inhibitor of IDO1/TDO2, as a potential immune-oncology therapeutic
    Gullapalli, Srinivas
    Roychowdhury, Abhijit
    Khaladkar, Tushar
    Sawargave, Sangameshaver
    Janrao, Ravindra
    Kalhapure, Vijay
    Urunkar, Ganesh
    Kulathingal, Jayanarayan
    Lekkala, Ramamohan Reddy
    Bhadra, Sonali
    Singh, Pankaj Kumar
    Putta, Krishna Anand
    Manwatkar, Sonali
    Surve, Prashant
    Gurjar, Mukund Keshav
    CANCER RESEARCH, 2018, 78 (13)
12345